Quick Answer
Immunome Inc. reported Cash and Equivalents of $653.48 million for fiscal year 2025.
Immunome Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $653.48M | +355.9% |
| 2024 | $143.35M | +45.3% |
| 2023 | $98.68M | +385.6% |
| 2022 | $20.32M | -58.7% |
| 2021 | $49.23M | +23.8% |
| 2020 | $39.77M | +1463.7% |
| 2019 | $2.54M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $272.64M | +75.3% | +89.5% |
| June 30, 2025 | $143.88M | -13.0% | -44.2% |
| March 31, 2025 | $257.61M | -4.5% | +79.7% |
| December 31, 2024 | $143.35M | +45.3% | -7.9% |
| September 30, 2024 | $155.57M | +71.6% | -5.9% |
| June 30, 2024 | $165.33M | +330.4% | -38.7% |
| March 31, 2024 | $269.72M | +507.2% | +173.3% |
| December 31, 2023 | $98.68M | +385.6% | +8.9% |
- Immunome Inc. showed an increase of +355.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Immunome Inc.’s cash and equivalents has grown by 25597.3% (from $2.54 million to $653.48 million).
- The most recent figure is from Immunome Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: